Sleep Control, GPCRs, and Glucose Metabolism.

Autor: Tsuneki H; Department of Clinical Pharmacology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan., Sasaoka T; Department of Clinical Pharmacology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Electronic address: sakurai.takeshi.gf@u.tsukuba.ac.jp., Sakurai T; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. Electronic address: tsasaoka@pha.u-toyama.ac.jp.
Jazyk: angličtina
Zdroj: Trends in endocrinology and metabolism: TEM [Trends Endocrinol Metab] 2016 Sep; Vol. 27 (9), pp. 633-642. Date of Electronic Publication: 2016 Jul 22.
DOI: 10.1016/j.tem.2016.06.011
Abstrakt: Modern lifestyles prolong daily activities into the nighttime, disrupting circadian rhythms, which may cause sleep disturbances. Sleep disturbances have been implicated in the dysregulation of blood glucose levels and reported to increase the risk of type 2 diabetes (T2D) and diabetic complications. Sleep disorders are treated using anti-insomnia drugs that target ionotropic and G protein-coupled receptors (GPCRs), including γ-aminobutyric acid (GABA) agonists, melatonin agonists, and orexin receptor antagonists. A deeper understanding of the effects of these medications on glucose metabolism and their underlying mechanisms of action is crucial for the treatment of diabetic patients with sleep disorders. In this review we focus on the beneficial impact of sleep on glucose metabolism and suggest a possible strategy for therapeutic intervention against sleep-related metabolic disorders.
(Copyright © 2016. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: